Venus Concept’s (VERO) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of Venus Concept (NASDAQ:VERO) in a research note released on Wednesday morning,Weiss Ratings reports.

Venus Concept Price Performance

Shares of NASDAQ:VERO opened at $2.35 on Wednesday. The business’s 50 day simple moving average is $2.36 and its 200-day simple moving average is $2.60. The firm has a market capitalization of $3.34 million, a price-to-earnings ratio of -0.05 and a beta of 0.05. The company has a debt-to-equity ratio of 5.72, a current ratio of 1.10 and a quick ratio of 0.71. Venus Concept has a 12 month low of $2.10 and a 12 month high of $14.50.

Venus Concept (NASDAQ:VERO) last posted its earnings results on Thursday, August 14th. The company reported ($8.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($9.72) by $1.69. Venus Concept had a negative return on equity of 871.77% and a negative net margin of 68.77%.The firm had revenue of $15.69 million for the quarter, compared to analyst estimates of $14.01 million.

Venus Concept Company Profile

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.